Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04080154 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma

ALTER-H-002
Start date: September 24, 2019
Phase: Phase 2
Study type: Interventional

This clinical study evaluates the efficacy and safety of anlotinib in patients with hepatocellular carcinoma who have progressed on lenvatinib treatment. It is a single arm, open-label clinical trial conducted in China, and plan to recruit 28 patients. Primary endpoint of the study is Progress Free Survival.

NCT ID: NCT04076631 Recruiting - Clinical trials for Hepatocellular Carcinoma

Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma

Start date: August 1, 2019
Phase:
Study type: Observational

The investigators intend to perform a prospective, multicenter study to establish a set of clinical criteria for surgical stages of liver cirrhosis, which can be implemented to guide the surgical treatment of hepatocellular carcinoma (HCC).

NCT ID: NCT04072679 Completed - Clinical trials for Advanced Hepatocellular Carcinoma

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Start date: October 11, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase Ib study to evaluate the safety, tolerability and efficacy of Sintilimab combined with IBI305 in patients with advanced hepatocellular carcinoma in China.

NCT ID: NCT04069949 Not yet recruiting - Clinical trials for Portal Vein Tumor Thrombus

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus

STUHCCPVTT
Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

NCT ID: NCT04069468 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

PROACTIF
Start date: March 13, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC) and liver metastases for colon cancer (mCRC) in real world clinical practice settings in France.

NCT ID: NCT04066660 Suspended - Clinical trials for Advanced Hepatocellular Carcinoma

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with metastatic colorectal cancer. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

NCT ID: NCT04066543 Recruiting - Clinical trials for Carcinoma, Hepatocellular

TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Start date: August 30, 2019
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.

NCT ID: NCT04053985 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Start date: January 1, 2018
Phase: Phase 3
Study type: Interventional

evaluation of the efficacy of transarterial chemoinfusion (TAI) combine lenvatinib in advanced hepatocelllar carcinoma

NCT ID: NCT04053972 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Start date: January 31, 2018
Phase: Phase 3
Study type: Interventional

To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.

NCT ID: NCT04053231 Not yet recruiting - Surgery Clinical Trials

Hepatocarcinoma Recurrence on the Liver Study - Part2

HERCOLES2
Start date: September 2019
Phase:
Study type: Observational [Patient Registry]

Rationale for the trial. To evaluate the impact of surgery on hepatocarcinoma recurrence. Thus, to evaluate the impact of different clinical, radiological, histopathological variables on recurrence after surgical treatment. The nature of this study will allow to observe, over time, the distribution of the considered collection variables, allowing a strictly observational monitoring of possible associations able to suggest models or interpretations, which can then be the basis for the construction of prospective and randomized studies.